Literature DB >> 10942328

Lung cancer treatment waiting times and tumour growth.

N O'Rourke1, R Edwards.   

Abstract

We report a single-centre prospective audit of 29 lung cancer patients who were awaiting radical (potentially curative) radiotherapy. This was the total number assessed as suitable for radical treatment by one consultant during 1999. At the time of assessment they had been newly diagnosed and staged with a computed tomographic (CT) scan of chest. They had a subsequent CT scan prior to starting treatment for the purpose of planning the radiation fields. We have now measured tumour size on the diagnostic scans and compared this with the size on the planning scans. We have documented the delay between diagnostic and planning CT scanning and the total time between first hospital visit and starting treatment. Two patients had progression of symptoms while on the waiting list, making them unfit for radical treatment, and another four had tumour progression on planning CT such that the tumour volume was too large for radical treatment. Therefore, 21% of potentially curable patients became incurable on the waiting list. The delay between diagnostic and planning CT scans ranged from 18 to 131 days (median 54), with increases in the cross-sectional tumour size over that period ranging zero to 373%. The delay between the first hospital visit and starting treatment was 35-187 days (median 94); between the date of the radiotherapy request and the starting date for treatment it was 23-61 days (median 44). Limited access to specialists is the reason most often advanced for the poor performance of the UK in treating lung cancer. This study demonstrates that, even for the select minority of patients who have specialist referral and are deemed suitable for potentially curative treatment, the outcome is prejudiced by waiting times that allow tumour progression.

Entities:  

Mesh:

Year:  2000        PMID: 10942328     DOI: 10.1053/clon.2000.9139

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  57 in total

1.  Radiotherapy units should be seen as shared resource in EU.

Authors:  I Kunkler
Journal:  BMJ       Date:  2001-10-27

2.  Doctors should tell patients truth about their waiting lists.

Authors:  N O'Rourke
Journal:  BMJ       Date:  2001-09-08

3.  Characteristics and predictors of missed opportunities in lung cancer diagnosis: an electronic health record-based study.

Authors:  Hardeep Singh; Kamal Hirani; Himabindu Kadiyala; Olga Rudomiotov; Traber Davis; Myrna M Khan; Terry L Wahls
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

4.  Guidelines for radiologically guided lung biopsy.

Authors:  A Manhire; M Charig; C Clelland; F Gleeson; R Miller; H Moss; K Pointon; C Richardson; E Sawicka
Journal:  Thorax       Date:  2003-11       Impact factor: 9.139

Review 5.  Cancer care in the United Kingdom: new solutions are needed.

Authors:  Karol Sikora; Nick Bosanquet
Journal:  BMJ       Date:  2003-11-01

6.  Effect of delays on survival in patients with lung cancer.

Authors:  Francisco Javier González-Barcala; José María García-Prim; José Manuel Alvarez-Dobaño; Milagros Moldes-Rodríguez; María Teresa García-Sanz; Antonio Pose-Reino; Luis Valdés-Cuadrado
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

Review 7.  The practice of thoracic surgery in Canada.

Authors:  Gail E Darling; Donna E Maziak; Joanne C Clifton; Richard J Finley
Journal:  Can J Surg       Date:  2004-12       Impact factor: 2.089

8.  Waiting for radiotherapy.

Authors:  D Dodwell; A Crellin
Journal:  BMJ       Date:  2006-01-14

9.  Time to treatment in patients with stage III non-small cell lung cancer.

Authors:  Li Wang; Candace R Correa; James A Hayman; Lujun Zhao; Kemp Cease; Dean Brenner; Doug Arenberg; Jeffery Curtis; Gregory P Kalemkerian; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-21       Impact factor: 7.038

Review 10.  Timing of curative treatment for prostate cancer: a systematic review.

Authors:  Roderick C N van den Bergh; Peter C Albertsen; Chris H Bangma; Stephen J Freedland; Markus Graefen; Andrew Vickers; Henk G van der Poel
Journal:  Eur Urol       Date:  2013-02-22       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.